The Status of Recombinant Reagents Used for Bacterial Endotoxin Testing (BET)

Monday Nov. 4, 2019 | 8am PT/11am ET

Sign Up:

First Name

* Required

Last Name

* Required

Company

* Required

Address Line 1

* Required

Address Line 2

* Required

City

* Required

State

* Required

Post Code or Zip

* Required

Country

* Required

Email *

* Required

Work Phone

* Required

May we contact you by email?

YesNo * Required

Would you like to receive more content from American Pharmaceutical Review? Please select below.

The webinar sponsor and CompareNetworks may use the information you have provided to contact you about this webinar and other related topics. For more information please refer to our privacy policy.

* Required

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

Overview

There has been a lot of discussion associated with the potential for use of synthetic (non-animal based) reagents for bacterial endotoxin testing. This webinar will provide an overview of the current status of the recombinant reagents on the global market. It will also lay out the recent proposed changes to USP <85>.

The second portion of the webinar will focus on specific examples of assays using recombinant reagents and their performance in samples and products as compared to the conventional amoebocyte lysate- based assays.

In this webinar you’ll learn about:

The current status of the recombinant reagents on the global market
Proposed changes to USP <85>
Specific examples of assays using recombinant reagents

Who should attend:

Quality control microbiology professionals (managers, supervisors, technicians) in pharmaceutical drugs and medical device companies
Compounding pharmacies

Presenters

Karen McCullough

Owner and Principal Consultant
MMI Associates
View Biography

Veronika Wills

Associate Director, Global Technical Services,
Associates of Cape Cod, Inc. (ACC)
View Biography